Home > Cluster Organisations > Hellenic BioCluster (HBio)

Hellenic BioCluster (HBio)

Primary tabs

Printer-friendly versionPrinter-friendly version
General Information
Year Established: 
Wednesday, 21 June, 2006
Number of employees in the cluster organisation : 
1-5
Regions: 
Aττική (Attiki)
Cluster Excellence Label: 
Bronze Label
Membership to other networks/partnerships: 
Cluster Management Team: 
NameSurnamePositionTelephoneEmail
ANDREAS
PERSIDIS
Cluster Manager
00302109629848
president@hbio.gr
DESPINA
ADAMIDOU
00302103611834
adamidou@help-forward.gr
IOANNIS
TRANTAKIS
Internationalisation Responsible
00302103607690
trantakis@hbio.gr
Languages spoken: 
English
French
Greek
Sectoral and Industrial Focus
Sectoral Industries: 
Biopharmaceuticals
Business Services
Education and Knowledge Creation
Technology fields: 
Cellular and Molecular Biology
Bioinformatics
Pharmaceutical Products / Drugs
S3 EU priority areas: 
e-Health (e.g. healthy ageing)
Human health activities (medical services)
Industrial biotechnology
Emerging industries: 
Bio-pharmaceuticals
Medical Devices
Composition of the cluster
Total number of members: 
38
Number of SME members: 
28
Number of larger company members: 
4
Number of research organisations/universities/technology centres: 
6
Entrepreneurship and start-up support organisations: 
Name and link of major players: 
NameTypeWebsite
PRAXI Network
Technology Center
BIOVISTA
SME
ELPEN
Larger Company
PHARMATHEN
Larger Company
PHARMASSIST
SME
IMBB
Research Organisation
Cluster Strategy
Mission/Objectives: 

The Hellenic BioCluster (HBio) is the first biosciences cluster in Greece bringing together the innovation leaders of Greece in the sectors of Pharmaceuticals, Biotechnology, Diagnostics, Medical Devices and Specialised Services. Established in 2006 by an initial group of 8 companies and the PRAXI Network, the technology transfer arm of the Foundation for Research & Technology- Hellas (FORTH), the Hellenic BioCluster has grown to date to over 30 innovation-intensive companies with an international outlook.  HBio aims to boost the development of the Life Sciences industry in Greece, to promote the Greek Life Sciences sector in the international scene and to facilitate business and research collaborations between local and international companies and research groups. HBio is a frequent interlocutor of the Hellenic government on matters of policy design in the areas of innovation support and life sciences strategy. It is also an active member of the Σynergies initiative which seeks to promote intra-sectoral collaborations in the high tech space. As part of its support of the next generations, HBio is a sponsor of conferences and student competitions related to the life sciences, innovation and youth entrepreneurship.

OUR VISION

Good health is at the centre of happy, productive lives. We believe that good science and a collaborative attitude are instrumental to advancing the state of the art and providing better health for all. We are working to support companies and research organisations in their international outlook and in their contribution to the global “health for all” effort.

OUR STRATEGIC GOALS

  • To promote the contribution and role of the Greek Healthcare industry on the global scene.
  • To foster collaborations between HBio members and international players.
  • To support members in their export orientation and international business development.
  • To foster the exchange of knowledge between HBio members and the international healthcare community.
  • To encourage and support entrepreneurship and innovation in the healthcare space.
Do you have a formalised strategy?: 
Yes
Do you have a specific strategy focus that addresses internationalisation ?: 
Yes
Services
Support services provided: 
Access to the European Internal market
Access to public support (regional/national programmes, innovation vouchers, etc.)
Facilitation of collaboration between members
Facilitation of cross-sectorial cooperation
Support of technology transfer
Details of support services: 
  • Promotion of the business & research activities of HBio members at national and international level, through European and international networks (as Enterprise Europe Network, through PRAXI Netrwork member)
  • Organisation of meetings/ workshops/ info-days, aiming at the promotion of networking between key players in the field of Life Sciences in Greece (companies, universities & research centres, hospitals & clinical laboratories, investors, national authorities and organisations)
  • Supporting business development by networking HBio members with national funding organisations and private equity/venture capital firms
  • Promoting the collective views & interests of its members to the National Authorities Facilitating the settlement of issues related to the economic/ legal/ regulatory framework in the Life Sciences business sector in Greece
  • Organisation of outward company missions to innovative bio-cluster regions in Europe and inward company missions tailored to HBio members needs Supporting HBio members for participation in international brokerage events
  • Networking HBio members with Greek & International research groups developing commercially exploitable technologies
  • Networking activities with basic players of the biotech sector in Greece and Europe
  • Promoting the participation of HBio members in National and European Research and Technological Development projects 
Cooperation Activities
International Cooperation
The main countries addressed by the cluster organisation through international activities: 
Brazil
Cyprus
Japan
Our cluster organisation undertook the following international activities to support our members: 
Participation at missions/events/study visits/fairs
Trans-national Cooperation
The main countries addressed by the cluster organisation through trans-national activities: 
Albania
Bulgaria
Italy
Poland
Spain
Our cluster organisation undertook the following trans-national activities to support our members: 
Participation at missions/events/study visits/fairs
Please explain: 

Mission to Brazil (under BBICE+ project)

Mission to Japan ( organised by EU- Japan Centre for Industrial Cooperation)

Project ECRI- under COSME- GA, Cluster Excellence Programme [ SPAIN- ITALY- POLAND] (November 2016)

Proposal submission under Interreg Balkan-Mediterranean Programme- S.O. competitiveness [BULGARIA- CYPRUS- ALBANIA]

Proposal submission under Interreg Balkan-Mediterranean Programme- S.O. knowledge [BULGARIA- CYPRUS]

 

Which clusters do you collaborate with?: 
bioPmed- Italy
Bioib- Spain
Kluster LifeScience Krakow- Poland
Support Programmes
Participation in Funded Support Programmes: 
Promotion
Success Story / Achievements: 

The Greek Biosciences Industry while in its early stages of development is experiencing a vigorous development phase. Established players are increasingly pursuing international R&D collaborations for the development of competitive technology-based products. Significant research discoveries have been made by local researchers and there are several start-up and spin-off companies emerging that are in the process of commercialising their innovations. At the same time, commercial companies witness growing turnovers and start investing in spin-offs and start-ups. Members' indicative success stories are following:

Biovista is a leading drug repositioning company with offices in Greece and the US.
Being 100% export oriented the company has major biopharma clients and collaborations with the FDA and a host of academic institutes. A recipient of the 2009 NE Venture Summit "Top Innovator Award" Biovista has filed over 10 patent applications, has readied a therapy for CFS for clinical trials in a record 24 months and has developed an approach to predicting adverse drug reactions that could revolutionize drug risk assessment and sub-population therapy optimization. A thought leader in the space, Biovista interacts with the governments in both Greece and the US on matters of public policy relating to healthcare, drug development and sustainable innovation. 

Micrel Medical Devices is quickly becoming a leader in Europe for ambulatory infusion devices and services.
In France the company won 90% of tenders in 2013 including UGAP and APHP Paris (the public hospital system in Paris). With 13 EP/US patents pipeline, we have two major technologies that will change infusion landscape in the future worldwide, a) MicrelCare a web based service that organizes all infusion tasks in our unique “GSM/GPRS connected” smart Rythmic(TM) pumps preventing errors and b) new disruptive (not yet disclosed) coin size high accuracy pump technology that makes possible prefilled smart labeled bags for higher volumes as opposed to prefilled syringes. International opinion leaders said this pump technology is 10 years ahead of any world competition.

ProtATonce is a hi-tech biotechnology company founded in 2012 and run by people from MIT and Harvard.
ProtATonce has achieved significant export activities by offering novel experimental and computational services in pharmaceutical, cosmetic, diagnostic, and life science companies. In contrast to all suggestions, ProtATonce stayed and build its facilities in Greece by supporting the local businesses, hiring highly qualified employees, and attracting highly qualified scientists from abroad. ProtATonce has 99% export activities and in less than two years of operation has achieved three major milestones: a) build state-of-the art facilities, b) developed strong and lasting partnerships with major companies worldwide, and c) broke even from $1M start up cost. ProtATonce has the goal to become a world leader service provider for early drug discovery and a model for successful biotech business made in Greece.

EMBIO Diagnostics (EMBIO) is the world leader in cell-based biosensors and an expert in the dissemination of biosensor technology at a global scale.
The company’s products are based on the internationally acclaimed technologies of the Bioelectric Recognition Assay and the Molecular Recognition through Membrane Engineering. Both technologies, protected by international patents, were created by a university-based research team, rendering EMBIO the most successful example of academic spin-out company in Greece and a milestone in public-private initiatives. Based on its unique technological advantage, EMBIO envisions the revolutionizing of medical diagnostics, biological warfare detection, food safety and agricultural production worldwide, through the development of portable, point-of-care (POC) diagnostic devices and the incorporation of highly advanced nanotechnological and biotechnological instrumentation in daily life. EMBIO is the recipient of the international CyEC2009 award. Among the company’s top products, FOODSCAN is the currently foremost system for food safety monitoring throughout Europe.

Why partners should choose you for cooperation?: 

HBio brings together the innovation leaders of Greece in the sectors of Pharmaceuticals, Biotechnology, Diagnostics, Medical Devices and Specialised Services. Our members invest in R&D, talent, state of -the-art equipment and aim to enhance their internationalisation capacity by adressing the global market standards.

HBio aims to be an active member of the international life sciences and healthcare community and a central point of contact for any stakeholder wishing to do business or collaborate with companies, academic institutions and other organisations in Greece.

WE OFFER

  • A central point of contact to most major biopharma organizations in Greece
  • Leadership in specific areas of interest including generics, drug formulation delivery and repositioning, diagnostics, clinical trials, animal model testing, specialist services and others
  • HBio can help your organization meet and collaborate with its members
  • HBio can provide advice in relation to local operations 
  • Links to government organisations and other clusters of potential relevance such as the Mobile Applications cluster for m-Health solutions